This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahdavi, A. Articles by Monk, B. J. Search for Related Content PubMed PubMed Citation Articles by Mahdavi, A. Articles by Monk, B. J.

Vaccines Against Human Papillomavirus and Cervical Cancer: Promises and Challenges

Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, USA

Correspondence: Bradley J. Monk, M.D., Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, 101 The City Drive, Building 56, Room 262, Orange, California 92868-3298, USA. Telephone: 714-456-7974; Fax: 714-456-6463; e-mail: bjmonk{at}uci.edu

	LEARNING OBJECTIVES

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
After completing this course, the reader will be able to:

1. Discuss the epidemiology and pathogenesis of HPV and HPV-associated diseases.
   
2. Explain the immune mechanisms relevant to the control of HPV infection.
   
3. Describe vaccine strategies for the prevention and therapy of HPV infection and cervical dysplasia and/or cancer.
   

	ABSTRACT

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Cervical cancer and precancerous lesions of the genital tract are major threats to the health of women worldwide. The introduction of screening tests to detect cervical cancer precursor lesions has reduced cervical cancer rates in the developed world, but not in developing countries. Human papillomavirus (HPV) is the primary etiologic agent of cervical cancer and dysplasia. Thus, cervical cancer and other HPV-associated malignancies might be prevented or treated by HPV vaccines. Two vaccine strategies have been developed. First, prevention of HPV infection through induction of capsid-specific neutralizing antibodies has been studied in clinical trials. However, because the capsid proteins are not expressed at detectable levels by infected basal keratinocytes or in HPV-transformed cells, a second approach of developing therapeutic vaccines by targeting nonstructural early viral antigens has also been developed. Because two HPV oncogenic proteins, E6 and E7, are critical to the induction and maintenance of cellular transformation and are coexpressed in the majority of HPV-containing carcinomas, most therapeutic vaccines target one or both of these gene products. A variety of approaches is being tested in therapeutic vaccine clinical trials, whereby E6 and/or E7 are administered in live vectors, as peptides or protein, in nucleic acid form, or in cell-based vaccines. The paradigm of preventing HPV infection through vaccination has been tested, and two vaccines are currently in phase III clinical trials. However, current therapeutic vaccine trials are less mature with respect to disease clearance. A number of approaches have shown significant therapeutic benefit in preclinical papillomavirus models and await testing in patient populations to determine the most effective curative strategy.

Key Words. Human papillomavirus • Vaccine • Cervical cancer • Cervical dysplasia

	INTRODUCTION

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Cervical cancer and precancerous cervical lesions constitute a major problem in women’s health. Clinical, molecular, and epidemiological investigations have identified human papillomavirus (HPV) as the major cause of cervical cancer and cervical dysplasia [1]. Virtually all cervical cancers (99%) contain the genes of high-risk HPVs, most commonly types 16,18, 31, and 45 [1].

Every year, 470,000 cases of cervical cancer are diagnosed worldwide, and about half of the women afflicted will die. In the U.S. alone, 50 million Pap tests are performed each year, and they discover close to 1.2 million cases of low-grade dysplasia (cervical intraepithelial neoplasia [CIN]1), 300,000 cases of high-grade dysplasia (CIN2/3) and 10,000 cases of cervical cancer [2]. The total health care cost associated with the screening and treatment of cervical cancer in the U.S. is estimated to be $6 billion per year. Although screening has dramatically reduced the incidence of this disease in the developed world, it is still estimated that there will be 3,710 deaths from cervical cancer in the U.S. during 2005. In areas of the world where most women do not have access to regular gynecological care and screening, cervical cancer is second only to breast cancer as a cancer-related cause of death [2].

Current treatment of cervical dysplasia is limited to excisional or ablative procedures that remove or destroy cervical tissue. These procedures have efficacy rates of approximately 90% but are associated with morbidity and expense. Additionally, surgical treatments remove only the dysplastic tissue, leaving normal-appearing HPV-infected tissue untreated [3]. It is therefore desirable to eradicate this infection using a vaccine, as was done previously with great success with hepatitis B. Preventive vaccination of adolescents before they first encounter HPV aims at this target. However, already-infected women as well as patients suffering from advanced cervical cancer could also benefit from therapeutic vaccinations under development. This article reviews the available information on prophylactic and therapeutic vaccines for HPV infection, with an emphasis on recent clinical trials.

HPV
HPVs belong to a family of small (8-kb pairs) double-stranded circular DNA viruses that infect squamous epithelia of the genital tract, anal, and perianal areas, and mucosal epithelium of the larynx. HPV-associated genital tract disease is now the most commonly diagnosed sexually transmitted disease in the U.S. Approximately 20 million people in the U.S. at any given time are infected with HPV and are able to transmit it to others. Low-risk HPVs, such as HPV-6 and HPV-11, cause benign genital warts, whereas high-risk types, such as HPV-16 and HPV-18, are associated with the development of high-grade squamous intraepithelial lesions and cervical cancer. It is estimated that HPV-16 accounts for approximately 60% of cervical cancers, with HPV-18 adding another 10%–20%. Other high-risk types include types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73.

Infection in both women and men is clearly related to sexual activity as well as environmental factors such as birth control pills and smoking. For women, the most striking risk factors for HPV infection and the development of detectable pathology are numerous lifetime sexual partners and early onset of sexual activity. Although HPV-related cancers are more common in women, increasing numbers of HPV-related carcinomas of the anal mucosa are being reported among men having sex with men [4]. A third group at risk for severe HPV infections is neonates. At birth, HPV can infect the mucosa of the pharynx and cause large wart-like lesions that can obstruct the airway.

To date, more than 100 genotypes of HPV have been described. Genotyping of HPV is based on DNA sequences of the L1, E6, and E7 genes. A 10% difference in sequence with respect to previously established strains is sufficient to define a new type of virus.

In general, HPV infects the basal cells of human epithelial surfaces. Infected basal cells divide; some progeny remain as infected basal cells, while others move away from the basement membrane, differentiate, and become epithelial cells. Virus replication and assembly is tightly linked to the differentiation program of epithelial cells. Infectious virions are produced only in the terminally differentiated cell and are shed as virus-laden squamous cells. This explains why HPV cannot grow in tissue culture.

By infecting only the basal layer cells and executing viral replication and assembly only in a fully differentiated cell, HPV avoids the immune system of the host. The success of this strategy is documented by very poor immune response (humoral as well as cell-mediated) to HPV infection. The nature of this response is under investigation; nevertheless, most women infected spontaneously resolve their infection in less than 2 years. Infections that are not controlled and persist for prolonged periods can cause more severe pathologies and, ultimately, cancer [5].

The HPV genome codes for only eight proteins (open reading frames). The late L1 and L2 genes code for the viral capsid proteins, the early proteins E1 and E2 are responsible for viral replication and transcription, and E4 seems to aid virus release from infected cells [6]. The early genes of the high-risk HPV types (E6 and E7) encode the main transforming proteins. These genes are capable of immortalization of epithelial cells and are thought to play a role in the initiation of the oncogenic process. The protein products of these early genes interfere with the normal function of tumor suppressor genes. HPV E6 is able to interact with p53, leading to its dysfunction, thereby impairing its ability to block the cell cycle when DNA errors occur. E6 also keeps the telomerase length above its critical point, protecting the cell from apoptosis. HPV E7 binds to retinoblastoma protein (pRb) and activates genes that start the cell cycle, leading to tissue proliferation. E5 has also been implicated in cellular transformation. Thus, there is now ample evidence based on molecular data alone that HPV has the tools to cause cancer.

Clinical, pathological, and virological studies have defined a progression of events in the development of cervical cancer. The pathogenesis of cervical cancer is initiated by HPV infection of the cervical epithelium during sexual intercourse. The initial cervical epithelial changes, pathologically classified as CIN1, are associated with continued viral replication and virus shedding. Progression to high-grade lesions (CIN2/3) and ultimately to invasive cancer is usually associated with conversion of the viral genome from an episomal form to an integrated form, along with deletion or inactivation of E2, a negative regulator of E6 and E7 expression. Development of invasive cancer requires additional genetic events facilitated by E6- and E7-mediated inactivation of the genome guardians p53 and pRb, genomic instability, and suppression of apoptosis [7].

Several studies have demonstrated that virus-neutralizing antibodies mediate protection of animals from experimental papillomavirus infection. For example, passive transfer of sera from virus-like particle (VLP)–vaccinated rabbits to naïve rabbits is sufficient for protection [8]. Similarly, vaccination with L2 peptides protects rabbits from papillomas resulting from viral but not from viral DNA challenge, consistent with the protection mediated by neutralizing antibodies [9].

Although antibody-mediated neutralizing of virus has important preventive utility, several lines of evidence suggest that cell-mediated immune responses are also important in controlling established HPV infections as well as HPV-associated neoplasms [10]: (a) The prevalence of HPV-related diseases (infections and neoplasms) is higher in patients with impaired cell-mediated immunity, including transplant recipients and HIV-infected patients; (b) animals immunized with nonstructural viral proteins are protected from papillomavirus infection and the development of neoplasia. Immunization also facilitates the regression of existing lesions; (c) Infiltrating CD4⁺ (T-helper cells) and CD8⁺ (cytotoxic T cells) cells have been observed in spontaneously regressing warts; (d) Warts in patients receiving immunosuppressive therapy often disappear when treatment is discontinued.

The well-characterized foreign (viral) antigens and the well-defined virological, genetic, and pathological progression of HPV have provided a unique opportunity to evaluate interventions with antigen-specific immunotherapy. Conceptually, two different types of HPV vaccines can be designed: prophylactic (preventive) vaccines that prevent HPV infection and therapeutic (curative) vaccines that induce regression of established HPV infection and its sequelae.

	VACCINE EFFICACY

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Traditionally, in etiological and cancer prevention studies, the measurable end point to determine efficacy of an intervention has been the incidence of cancer itself. But as some cancers take a long time to develop and are not common in a given population, trials with an end point of invasive cancer can be prohibitively large and lengthy. In the case of cervical cancer, a disease that can be prevented through proper detection and treatment, a study end point of cancer can be ethically impracticable. Recently, the U.S. Food and Drug Administration Vaccines and Related Biologicals Advisory Committee concluded that the primary end point for vaccine licensure in the U.S. should be CIN2/3 as well as cancer [11]. Because persistent infection with the same high-risk type is considered a predictor for high-grade cervical dysplasia and cancer, these surrogate end points might be useful in future vaccine efficacy studies. Indeed, if vaccines prove to be effective against transient or especially persistent HPV infections, it is likely that they will protect women against cervical cancers as well.

An ideal prophylactic vaccine needs to possess several attributes [12]. It should be safe, because it would be given to young, normal individuals, the vast majority of whom, even without a vaccine, would not be expected to develop cancer from HPV infection. It should be able to be administered in settings with poor resources, be inexpensive, and be effective after a single dosage. Protection should last many years and the vaccine should confer a substantial reduction in the incidence of cervical cancer. However, it is difficult to define precisely what degree of reduction in cervical cancer would justify the widespread use of an HPV vaccine. Mammography is recommended for breast cancer screening, although it is believed to reduce breast cancer deaths by no more than one third. By comparison, an HPV vaccine that successfully targeted all cervical cancer cases attributable to HPV-16 alone would be expected to reduce the worldwide incidence of cervical cancer by more than half. In countries with effective population-wide cervical cancer screening programs, other considerations are whether the introduction of a vaccine might be able to reduce the physical, psychological, and financial costs associated with screening and follow-up through a reduction in the frequency of detection of cervical abnormalities and/or the frequency of screening.

	PROPHYLACTIC VACCINE

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Probably the most important contribution to the field of HPV vaccine development came in 1991, when Zhou et al. [13] showed that HPV-16 L1 capsid protein, when expressed in a recombinant system, formed virus-like particles (VLPs) that resembled native virions. These VLPs have been proven to be highly antigenic. Parenteral injection of these VLPs elicits high titers of serum-neutralizing antibodies and protection from experimental viral challenge with infectious virus in several animal papillomavirus models.

Protection from experimental infection by cottontail rabbit papillomavirus (CRPV) or canine oral papillomavirus after passive transfer of IgG from VLP-immunized animals to naïve animals has been demonstrated in rabbits and dogs, respectively [8, 14]. The results from these protective vaccine studies indicate that neutralizing IgG provides protection from experimental infection.

Although VLP vaccination provides immunity from experimental inoculation, protection against sexual transmission of HPV requires neutralizing antibodies acting on mucosal surfaces. Serum-neutralizing IgG induced by parenteral VLP vaccination may enter the genital tract via transudation and maintain a sufficient level to provide sterilizing immunity across the menstrual cycle. Neutralizing antibodies may either transudate from plasma into genital secretions or be synthesized by local plasma cells; induction of plasma cells requires direct immunization of mucosa-associated lymphoid tissue [15]. Recently, nasal instillation of VLPs has been found to be efficient in generating specific antibodies, including IgG in serum and IgA in mucosal secretions of mice [16]. Oral vaccination with HPV VLPs in mice has also been shown to induce systemic virus-neutralizing antibodies, suggesting that HPV VLPs may be antigenically stable in the environment of the gastrointestinal tract. Recently, Liu et al. [17] showed that HPV-16 L1 protein could be expressed in transgenic tobacco plants and that the expressed protein possessed the natural features of HPV-16 L1 protein, implying that the HPV-16 L1 transgenic plants could be potentially used as an edible vaccine. These studies provide the possibility of vaccinating large populations with HPV VLPs without using syringes.

In recent clinical data, intramuscular vaccination of women with HPV-16 VLPs was found to induce significant antibody titers in cervical secretions [18]. A comparison of nasal spray versus aerosol for mucosal delivery of 50 µg of HPV-16 VLPs to humans revealed that aerosol was effective at inducing an antibody response, with IgG found predominantly in serum and both IgG and IgA found in cervical secretions.

Phase I/II clinical trials using HPV L1 VLPs delivered intramuscularly have demonstrated the immunogenicity and safety of this vaccine. Koutsky et al. [19] recently reported data from a clinical trial of HPV-16 L1 VLPs, showing for the first time that a vaccine strategy could be implemented in humans to prevent HPV-16 infection and HPV-16–associated premalignant lesions. Young women (n = 2,392) were assigned to receive either placebo or yeast-derived HPV-16 L1 VLPs (40-µg dosage), formulated on 225 µg aluminum hydroxy phosphate sulfate adjuvant (Merck & Co., Inc., Whitehouse Station, NJ, http://www.merck.com), at month 0, month 2, and month 6 by intramuscular injection (Table 1). Samples from the genital tract were obtained at enrollment, 1 month after the booster immunization, and every 6 months thereafter. In addition, the women underwent gynecological examinations and were referred for colposcopy according to the protocol. Biopsy tissue was evaluated for intraepithelial neoplasia and analyzed by polymerase chain reaction (PCR) for the presence of HPV-16 DNA. DNA was prepared from the specimen using routine methods. HPV-16 DNA was amplified by PCR using type- and gene-specific primers for the HPV-16 L1, E6, and E7 genes. PCR products were visualized by dot-blot hybridization using type- and gene-specific oligonucleotides. The assays were validated to have a 95% probability of detecting 13 copies of HPV-16 DNA per sample. The primary end point of the trial was persistent HPV-16 infection, defined as: (a) HPV-16 DNA detected in samples obtained at two or more visits at least 4 months apart; (b) a cervical biopsy showing CIN or cancer and HPV-16 DNA in the biopsy and in a genital sample collected at the antecedent or subsequent visit; or (c) HPV-16 DNA detected in a sample collected during the last visit before being lost to follow-up.

In another recent, randomized, double-blinded, controlled trial, Harper et al. [21] assessed the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 VLP vaccine for the prevention of incident and persistent infections with these two virus types, associated cervical cytological abnormalities, and precancerous lesions. They randomized 1,113 women between 15 and 25 years of age to receive three dosages of either the vaccine, formulated with 500 µg aluminum hydroxide and 50µg3-deacylated monophosphoryllipid (AS04) adjuvant, or placebo at 0, 1, and 6 months in North America and Brazil (Table 1). Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vaccine safety and immunogenicity. In the according-to-protocol analyses, vaccine efficacy was 91.6% (95% CI, 64.5%–98.0%) against incident infection and 100% against persistent infection with HPV-16/18. In the intent-to-treat analyses, vaccine efficacy was 95.1% against persistent cervical infection with HPV-16/18 and 92.9% against cytological abnormalities associated with HPV-16/18 infection. The vaccine was generally safe, well tolerated, and highly immunogenic.

These two high-quality studies showed that HPV vaccines were not only safe and well tolerated but were also efficacious in the prevention of incident and persistent cervical HPV infections and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce the incidence of cervical cancer.

Merck and GlaxoSmithKline (Philadelphia, http://www.gsk.com) are currently conducting phase III clinical trials to assess the efficacy of quadrivalent HPV-6/11/16/18 and bivalent HPV-16/18 vaccines, respectively.

From a technical perspective, vaccination with VLPs appears promising. Nevertheless, several practical issues must be addressed before these vaccines can be licensed and deployed in clinical practice and public health programs [6]. Regarding the optimal age for vaccination, it is estimated that an HPV-16/18 vaccine for 12-year-old girls would reduce cohort cancer cases by 61.8% with a cost-effectiveness ratio of $14,583 per quality-adjusted life year (QALY) [22]. Including male participants in a vaccine rollout would further reduce cervical cancer cases by only 2.2% at an incremental cost-effectiveness ratio of $442,039/QALY compared with female-only vaccination. Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared with female-only vaccination.

Even if HPV vaccines are shown to be safe and effective, marketing a vaccine against a sexually transmitted disease to the general public may be problematic. Parental resistance can easily be imagined. The most effective strategy is to maintain philosophical distance from sexual aspects of the question and focus on the prevention of a common cause of cancer. In a recent survey by Slomovitz et al. [23], 75% of women accepted a cervical cancer vaccine for themselves and 70% accepted such a vaccine for their children.

	THERAPEUTIC VACCINES

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Even if prophylactic vaccination was instituted on a worldwide scale today, it would take decades (because of the long latency from HPV infection to the development of cervical cancer) to perceive the benefits; that is, lower incidences of cervical preinvasive and invasive disease. Therapeutic vaccines are a means of bridging the temporal deficit by attacking already-established HPV infections and HPV-related disease in the lower genital tract [24]. In contrast to preventive vaccines, HPV therapeutic vaccines need to include some antigenic determinants derived from the early HPV proteins (e.g., E2, E6, and E7) rather than the late proteins. This has proved to be a much more challenging task in terms of biodelivery and response. Whereas most tumor-specific antigens are derived from normal or mutated proteins, E6 and E7 are completely foreign viral proteins, and thus may harbor more antigenic peptides/epitopes than a mutant cellular protein. Furthermore, because E6 and E7 are required for the induction and maintenance of the malignant phenotype of cancer cells, cervical cancer cells are unlikely to evade an immune response through antigen loss. Thus, E6 and E7 proteins represent good targets for developing antigen-specific immunotherapies or vaccines for cervical cancer. It should be highlighted that cellular immune response appears to be the key component necessary for clearance of HPV infections and therefore would be the main target of any therapeutic HPV vaccine.

Various forms of HPV vaccines have been described in experimental systems targeting HPV-16 E6 and E7 proteins (Table 2). Most studies have focused on E7, because it is more abundantly expressed and better characterized immunologically [25, 26]. Furthermore, its sequence is more conserved than that of the E6 gene.

Studies using modified adenovirus-expressing HPV-16 E6 or E7 for vaccination [30] or for ex vivo preparation of dendritic cell (DC)–based vaccines have demonstrated enhancement of antigen-specific T-cell immune responses and antitumor effects. Replication-defective adeno-associated virus encoding HPV-16 E7 fused to heat-shock protein 70 was found to induce CD4- and CD8-dependent CTL activity and antitumor effects in vitro [31].

Bacterial Vector Vaccines
Bacterial vector vaccines are highly immunogenic and can deliver engineered plasmids or express proteins. As with viral vaccines, safety concerns, pre-existing immunity, and inhibited repeat immunization limit their clinical application. Attenuated bacteria (e.g., Listeria monocytogenes, Salmonella, Shigella, Escherichia coli) can serve as bacterial carriers to deliver either plasmids encoding genes of interest or proteins of interest to antigen-presenting cells (APCs). L. monocytogenes produces listeriolysin O, which allows escape into the cytoplasm after phagocytosis by macrophages and facilitates delivery of antigens into both MHC-I and MHC-II pathways. Recent studies have found that intraperitoneal or oral vaccination with recombinant L. monocytogenes secreting HPV-16 E7 can lead to regression of pre-existing E7-expressing murine tumors [32]. Attenuated Salmonella and Bacille Calmette-Guerin (Mycobacterium bovis) are safe bacterial vaccine vectors that have been used to develop vaccines encoding HPV-16 L1 and E7 and have been found to induce E7-specific antibody and cytotoxic immune responses [33].

Peptide Vaccines
Peptide vaccines have the advantages of safety and ease of production; however, their weak immunogenic properties and the need for HLA matching must be overcome. Because 40% of Caucasians carry the HLA-A2 alleles, HPV-16 E7 peptides presented by this allele have been the immunogen in several phase I/II clinical trials [34]. Ressing et al. [35] performed a peptide-based phase I/II vaccination trial to induce antitumor immune responses in patients with recurrent or residual cervical carcinoma. Fifteen HLA-A*0201–positive patients with HPV-16–positive cervical carcinoma received vaccinations with synthetic peptides representing two HPV-16 E7–encoded, HLA-A*0201–restricted CTL epitopes and a pan-HLA-DR–binding T-helper epitope, in adjuvant. No signs of toxicity were observed. Two patients had stable disease for more than 1 year after vaccination, three patients died of the disease during or shortly after the vaccination period, and 10 patients maintained progressive cervical carcinoma [36].

In another study [37], 18 women with high-grade cervical or vulvar dysplasia who were positive for HPV-16 and HLA-A2 were treated with escalating dosages of a vaccine consisting of a nine–amino acid peptide encoded by the E7 gene emulsified with incomplete Freund’s adjuvant. They received four immunizations of the vaccine each, 3 weeks apart, followed by a repeat colposcopy and definitive removal of dysplastic tissue 3 weeks after the fourth immunization. Only three of the 18 patients were free of dysplasia after vaccination, but an increased S100⁺ DC infiltrate was observed in six of six patients tested. Virological assays showed that 12 of 18 patients showed no virus in cervical scrapings by the fourth vaccine injection, but all biopsy samples were still positive by in situ RNA hybridization after vaccination. In addition to the three complete responders, six patients had partial colposcopically measured regression of their CIN lesions.

Protein Vaccines
Whereas peptide vaccines exhibit MHC restriction, protein-based vaccines can bypass this restriction and thus are less dependent on the patient’s HLA type (Table 2). TA-GW fusion protein, which consists of HPV-6 L2 fused to E7 protein, has been successfully tested for the clinical treatment of genital warts [38]. TA-CIN fusion protein, which consists of HPV-16 L2/E6/E7, can induce E7-specific CD8⁺ T-cell immune responses and tumor protection in mice. TA-CIN was well tolerated by patients and induced both humoral and T-cell–mediated immune responses [39].

The potency of HPV-16 E7 peptide–based vaccines may be further enhanced through the use of adjuvants, fusion proteins, or anchor-modified peptide epitopes. Chu et al. [40] demonstrated that adjuvant-free immunization of C57B1/6 mice with heat shock protein E7 (hspE7) protected the animals against challenge with an E7-expressing murine tumor cell line (TC-1) and also protected against rechallenge with higher doses of TC-1 cells. Similarly, immunization of tumor-bearing mice with hspE7 led to tumor regression, protection from rechallenge, and long-term survival. Tumor regression after hspE7 immunization appeared to be dependent on CD8⁺ T cells, but independent of CD4⁺ T cells. More recently, in a single-stage phase II study (Table 3), Einstein et al. [41] administered three monthly hspE7 vaccines to 31 women with biopsy-proven CIN3. At 4 months, all patients underwent a loop electro-surgical excision procedure or cone biopsy. A complete pathologic response was defined as no evidence of CIN or CIN1. A partial response was defined as colposcopic regression of the lesion by more than 50%. hspE7 vaccine treatment resulted in a significantly higher than expected pathologic response rate among women with CIN3: 48% had complete responses, 19% had partial responses, and 33% had stable disease. No patient had progressive disease. The responses were not significantly associated with HPV-16 infection status or infection with multiple subtypes; however, the sample size was limited. hspE7 vaccine is now in clinical trials with Stressgen Biotechnologies (Victoria, British Columbia, Canada http://www.stressgen.com) to treat asymptomatic HPV infections, HPV-associated anal dysplasia, and HPV-associated cervical cancer. A phase II evaluation of SGN-00101 (hspE7) fusion protein in women with CIN3 is under way by the Gynecologic Oncology Group (GOG protocol #197).

Due to the weak intrinsic potency of naked DNA vaccines, various strategies have been developed to enhance their immunogenicity. Because DCs are the primary mediators of DNA vaccine–induced immune responses, vaccines that modify intracellular or intercellular movement of antigen or other DC properties are able to enhance DNA vaccine potency. Because DCs have a limited lifespan, a method to prolong in vivo DC survival may help improve DNA potency. Coadministration of E7-containing DNA with DNA-encoding antiapoptotic proteins (Bcl-xl, Bcl-2) is able to enhance E7-specific immune responses, tumor treatment, and DC survival [42].

Another strategy to improve delivery and antigenicity of HPV DNA vaccines is the use of encapsulation. Garcia et al. [43] reported on the use of encapsulated plasmid DNA-encoding fragments derived from E6 and E7 of HPV-16 and HPV-18 in biodegradable particles (ZYC101a). Their study population included women with biopsy-confirmed CIN2 or CIN3 (Table 3). The study design was double-blinded, randomized, and placebo-controlled and was carried out in multiple centers in the U.S. and Europe. A total of 161 patients was evaluated for efficacy and safety, but only 127 were evaluable for efficacy after pathologic review of the cases. Two dosages of the vaccine (100 µg and 200 µg) were evaluated against a saline placebo. Patients were injected at 0, 3, and 6 months. Approximately 6 months after study entry, all patients underwent an excisional procedure of the cervix, most often a loop electrosurgical excision procedure. Patients were monitored with periodic colposcopic evaluations, cytology, and HPV testing. There were statistically significant higher incidences of injection site pain, erythema, and induration in the treatment groups than in the placebo group, but no other adverse events differed significantly between the treatment and placebo groups. For analysis purposes, patients were divided into two age categories, defined as <25 years of age and >25 years of age. There was a statistically significant higher rate of CIN2 or CIN3 resolution in the <25 years of age group (placebo, 23%; 100 3g, 67%; and 200 µg, 72%). However, there was no difference in resolution rates between vaccine (either dosage) and placebo in the group >25 years of age. Neither immune parameters nor other variables, such as tobacco use or infection with specific HPV types, correlated with response or lack thereof. This vaccine has been acquired by MGI Pharmaceuticals (Bloomington, MN, http://www.mgipharma.com) and further studies are planned.

DC-Based Vaccines
DCs are the most important APCs in the immune system. Techniques have been developed for isolation, culturing, and antigen loading. Santin et al. [44] demonstrated that recombinant, full-length, E7-pulsed, autologous DCs could elicit a specific CD8⁺ CTL response against autologous tumor target cells in three patients with HPV-16– or HPV-18–positive cervical cancer. Their results demonstrated that full-length, E7-pulsed DCs could induce both E7-specific CD4⁺ T-cell proliferative responses and strong CD8⁺ CTL responses capable of lysing autologous HPV-infected cancer cells in patients with cervical cancer. In another study [45], 15 patients with stage IV cervical cancer were treated with autologous monocyte-derived DCs that had been pulsed with recombinant HPV-16 E7 or HPV-18 E7 onco-protein. Specific cellular immune responses were detected in four of the 11 patients. A transient drop in a squamous cell carcinoma tumor marker was documented in five of nine patients but did not correlate with immune response.

Tumor Cell–Based Vaccines
Transduction of tumor cells with genes encoding costimulatory molecules or cytokines may enhance immunogenicity, leading to T-cell activation and antitumor effects after vaccination. Vaccines using HPV-transformed tumor cells transduced with cytokine genes, such as interleukin-12, interleukin-2, or GM-CSF [46], can generate strong antitumor effects in mice.

Combined Approaches
With this approach, it is hoped that combining vaccine vehicles using a "prime-boost" strategy might allow priming the immune system with one vaccine technology, followed by augmenting and maintaining a long-term immune response with another boosting vaccine. Indeed, Chen et al. [47] have suggested that priming with a DNA vaccine followed by a recombinant vaccinia booster might provide the most potent anti-HPV effects.

Another combination approach involves the simultaneous administration of DNA vaccines and other antiviral or anticancer agents. Christensen et al. [48] topically administered the antiviral agent cidofovir (Vistide^®; Gilead Sciences, Foster City, CA, http://www.gilead.com) and intra-cutaneously administered DNA vaccine encoding CRPV genes. Cures of large, established, CRPV-induced rabbit papillomas and a lower incidence of lesion recurrence were observed, suggesting that this combination may also be useful in treating persistent HPV infections.

	COMBINED PROPHYLACTIC AND THERAPEUTIC VACCINES

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Therapeutic vaccination may be useful in the treatment of premalignant lesions in conjunction with prophylactic strategies. It has been shown that VLPs can activate DCs, and HPV-16 VLP-E7 chimera vaccines can generate useful T-cell responses to E7 [49], as well as neutralizing antibodies to viral capsids. This approach could provide a means to effectively treat incident HPV infection. The risk for cancer development from long-term HPV infection could be managed with local treatment and immunization in these patients, but as is presumably the case now, most individuals would develop effective natural immunity.

	CONCLUSION AND FUTURE DIRECTIONS

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
HPV is a ubiquitous virus. However, the infection is often transient and self-limiting. Several studies have suggested that HPV infection and cervical dysplasia can be prevented by HPV L1 VLP vaccines. It is anticipated that "second-generation" prophylactic vaccines that target neutralizing epitopes from both L1 and L2 as well as therapeutic antigens will increase the spectrum of covered oncogenic genotypes.

Therapeutic vaccines present far more challenges than prophylactic vaccines. The challenges include the immuno-compromised state of cancer patients, difficulty in stimulating the immune system, immune escape mechanisms used by tumors and virally infected cells, and safety concerns. Despite these challenges, there are many encouraging results suggesting that T-cell responses to the E6/E7 proteins can be generated in animal models as well as in humans.

Much still needs to be investigated regarding local immune responses in the lower genital tract, longevity of immune responses, and alternative delivery routes, such as intravaginal, intranasal, and oral administration. This is an exciting time for HPV vaccine research; HPV vaccine strategies have the potential to eradicate a major cancer and source of morbidity around the world.

	DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 
Dr. Monk receives research support from MGI, Digene, and Cyto.

	REFERENCES

Top Learning Objectives Abstract Introduction Vaccine Efficacy Prophylactic Vaccine Therapeutic Vaccines Combined Prophylactic and... Conclusion and Future Directions Disclosure of Potential... References

 

1. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.[CrossRef][Medline]
2. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122–163.[Free Full Text]
3. Bell MC, Alvarez RD. Chemoprevention and vaccines: a review of the nonsurgical options for the treatment of cervical dysplasia. Int J Gynecol Cancer 2005;15:4–12.[CrossRef][Medline]
4. Goldstone SE, Winkler B, Ufford LJ et al. High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. Dis Colon Rectum 2001;44:690–698.[CrossRef][Medline]
5. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20–25.[CrossRef][Medline]
6. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004;55:319–331.[CrossRef][Medline]
7. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342–350.[CrossRef][Medline]
8. Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959–3963.[Abstract/Free Full Text]
9. Embers ME, Budgeon LR, Pickel M et al. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002;76:9798–9805.[Abstract/Free Full Text]
10. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004;35:971–982.[CrossRef][Medline]
11. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569–578.[CrossRef][Medline]
12. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003;(31):111–116.
13. Zhou J, Sun XY, Stenzel DJ et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251–257.[CrossRef][Medline]
14. Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995;92:11553–11557.[Abstract/Free Full Text]
15. Russell MW, Moldoveanu Z, White PL et al. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun 1996;64:1272–1283.[Abstract/Free Full Text]
16. Nardelli-Haefliger D, Roden RB, Benyacoub J et al. Human papilloma-virus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997;65:3328–3336.[Abstract/Free Full Text]
17. Liu HL, Li WS, Lei T et al. Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants. Acta Biochim Biophys Sin (Shanghai) 2005;37:153–158.
18. Nardelli-Haefliger D, Wirthner D, Schiller JT et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003;95:1128–1137.[Abstract/Free Full Text]
19. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–1651.[Abstract/Free Full Text]
20. Ferris D, Koutsky L, Wehren L et al. Reduction in CIN following prophylactic HPV type 16 vaccination. Gynecol Oncol 2005;96:911a–912a.
21. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757–1765.[CrossRef][Medline]
22. Taira AV. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915–1923.[Medline]
23. Slomovitz BM, Sun CC, Frumovitz M et al. Are women ready for the cervical cancer vaccine? Gynecol Oncol 2005;96:912a.
24. Padilla-Paz LA. Human papillomavirus vaccine: history, immunology, current status, and future prospects. Clin Obstet Gynecol 2005;48:226–240.[CrossRef][Medline]
25. Ahn WS, Bae SM, Kim TY et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003;14:1389–1399.[CrossRef][Medline]
26. Jochmus-Kudielka I, Schneider A, Braun R et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698–1704.[Abstract/Free Full Text]
27. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523–1527.[CrossRef][Medline]
28. Davidson EJ, Boswell CM, Sehr P et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003;63:6032–6041.[Abstract/Free Full Text]
29. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005;32(suppl 1):S72–S81.
30. He Z, Wlazlo AP, Kowalczyk DW et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000;270:146–161.[CrossRef][Medline]
31. Liu DW, Tsao YP, Kung JT et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000;74:2888–2894.[Abstract/Free Full Text]
32. Gunn GR, Zubair A, Peters C et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471–6479.[Abstract/Free Full Text]
33. Jabbar IA, Fernando GJ, Saunders N et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000;18:2444–2453.[CrossRef][Medline]
34. Steller MA, Gurski KJ, Murakami M et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4:2103–2109.[Abstract]
35. Ressing ME, Sette A, Brandt RM et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934–5943.[Abstract]
36. Ressing ME, van Driel WJ, Brandt RM et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;23:255–266.
37. Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406–3416.[Abstract/Free Full Text]
38. Lacey CJ, Thompson HS, Monteiro EF et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612–618.[CrossRef][Medline]
39. de Jong A, O’Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456–3464.[CrossRef][Medline]
40. Chu NR, Wu HB, Wu T et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121:216–225.[CrossRef][Medline]
41. Einstein MH, Kadish AS, Burk RD et al. HSP-based immunotherapy (HspE7) for treatment of CIN 3. Gynecol Oncol 2005;96:912a–913a.
42. Kim TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003;112:109–117.[CrossRef][Medline]
43. Garcia F, Petry KU, Muderspach L et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103:317–326.[Medline]
44. Santin AD, Hermonat PL, Ravaggi A et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 1999;73:5402–5410.[Abstract/Free Full Text]
45. Ferrara A, Nonn M, Sehr P et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003;129:521–530.[CrossRef][Medline]
46. Chang EY, Chen CH, Ji H et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000;86:725–730.[CrossRef][Medline]
47. Chen CH, Wang TL, Hung CF et al. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000;18:2015–2022.[CrossRef][Medline]
48. Christensen ND, Pickel MD, Budgeon LR et al. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res 2000;48:131–142.[CrossRef][Medline]
49. Greenstone HL, Nieland JD, de Visser KE et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 1998;95:1800–1805.[Abstract/Free Full Text]

This article has been cited by other articles:

				H. Liu, B. H. Wu, G. J. Rowse, and P. C. R. Emtage Induction of CD4-Independent E7-Specific CD8+ Memory Response by Heat Shock Fusion Protein Clin. Vaccine Immunol., August 1, 2007; 14(8): 1013 - 1023. [Abstract] [Full Text] [PDF]

				B. J. Monk, K. S. Tewari, and W.-J. Koh Multimodality Therapy for Locally Advanced Cervical Carcinoma: State of the Art and Future Directions J. Clin. Oncol., July 10, 2007; 25(20): 2952 - 2965. [Abstract] [Full Text] [PDF]

				M. R. Gabri, Z. Mazorra, G. V. Ripoll, C. Mesa, L. E. Fernandez, D. E. Gomez, and D. F. Alonso Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model Clin. Cancer Res., December 1, 2006; 12(23): 7092 - 7098. [Abstract] [Full Text] [PDF]

				D. van Hamont, M. A. P. C. van Ham, J. M. J. E. Bakkers, L. F. A. G. Massuger, and W. J. G. Melchers Evaluation of the SPF10-INNO LiPA Human Papillomavirus (HPV) Genotyping Test and the Roche Linear Array HPV Genotyping Test J. Clin. Microbiol., September 1, 2006; 44(9): 3122 - 3129. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				I. de Melo-Martin The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection. Oncologist, April 1, 2006; 11(4): 393 - 396. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahdavi, A. Articles by Monk, B. J. Search for Related Content PubMed PubMed Citation Articles by Mahdavi, A. Articles by Monk, B. J.